Profile: U.S. Genomics

Matt Kelly, PERSONAL MEDICINE IN WAITING ROOM, U.S. GENOMICS FINDS SMALLER MARKET. Small Times. Feb 16 2004.

Zachary Zimmerman, an analyst with Life Sciences Insights, pegs the genome sequencing market at about $800 million annually, with Applied Biosystems owning at least 80 percent of it. Zimmerman says startups like U.S. Genomics must still prove their technology, but he expects pharmaceuticals to swoon once they believe high-speed sequencing works.

By the way, Life Sciences Insights is a research and advisory practice launched this month by IDC.

 

Comments

Comments are closed.